参考文献/References:
[1] MICHAL FREEDMAN D, WU Jincao, CHENHonglei, et al. Associations between cancer andParkinson’s disease in U.S. elderly adults[J].International Journal of Epidemiology, 2016, 45(3):741-751.
[2] GOEDERT M, COMPSTON A. Parkinson’s disease -the story of an eponym[J]. Nature Reviews Neurology,2018, 14(1): 57-62.
[3] ARMSTRONG R A. Visual dysfunction in Parkinson’sdisease[J]. International Review of Neurobiology, 2017,134(6): 921-946.
[4] 周梅,余丹.血清微小RNA-221, 微小RNA-214 在帕金森病中的表达及其与帕金森综合评分的相关性研究[J]. 中国医刊, 2020, 55 (2): 206-209.ZHOU Mei, YU Dan. Research on expression of serummicroRNA-221 and microRNA-214 in Parkinson’sdisease and their correlation with Parkinson’scomprehensive score [J]. Chinese Medical Journal,2020, 55 (2): 206-209.
[5] WANG Jin, CHEN Jinyun, SEN S. MicroRNA asbiomarkers and diagnostics[J]. Journal of CellularPhysiology, 2016, 231(1): 25-30.
[6] LIN Yihai, WU Zhangyi. MicroRNA-128 inhibitsproliferation and invasion of glioma cells by targetingCOX-2[J]. Gene, 2018, 658(6): 63-69.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南( 第三版)[J]. 中华神经科杂志,2014,43(6):428-433.Chinese Society of Parkinson’s Disease and MovementDisorders. Chinese guidelines for the treatment ofParkinson’s disease (3rd Edition) [J]. Chinese Journalof Neurology, 2014, 43 (6): 428-433
[8] STORCH A, SCHNEIDER C B, KLINGELH?FERL, et al. Quantitative assessment of non-motorfluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS)[J]. Journal of NeuralTransmission (Vienna, Austria : 1996), 2015, 122(12):1673-1684.
[9] 刘郁,张静静,吕荣祥,等.miR-143-3p 和BCL2在早发性帕金森病患者血清胞外囊泡中异常表达[J]. 中华神经医学杂志,2019,18(1):17-21.LIU Yu, ZHANG Jingjing, L? Rongxiang, et al.Abnormal expressions of micro RNA-143-3p and B-celllymphoma-2 in serum extracellular vesicles of patientswith early-onset Parkiuson’s disease [J]. ChineseJournal of Neuromedicine, 2019, 18 (1): 17-21
[10] 乔迪, 江沛, 伊新艳, 等. 微小RNA 在帕金森病中调节α- 突触核蛋白表达的研究进展[J]. 中南药学,2017,15(8):1085-1088.QIAO Di, JIANG Pei, YI Xinyan, et al. Role ofmicroRNAs in regulating α-synuclein expression inParkinson’s disease [J]. Central South Pharmacy, 2017,15 (8): 1085-1088.
[11] LEE H C, JUNG S H, HWANG H J, et al. WIG1is crucial for AGO2-mediated ACOT7 mRNAsilencing via miRNA-dependent and -independentmechanisms[J]. Nucleic Acids Research, 2017, 45(11):6894-6910.
[12] WANG C, GUPTA P, FRESSIGNE L, et al. TEG-1CD2BP2 controls miRNA levels by regulating miRISCstability in C. elegans and human cells[J]. NucleicAcids Research, 2017, 45(3): 1488-1500.
[13] ZANGARI J, ILIE M, ROUAUD F, et al. Rapid decayof engulfed extracellular miRNA by XRN1 exonucleasepromotes transient epithelial-mesenchymal transition[J].Nucleic Acids Research, 2017, 45(7): 4131-4141.
[14] 韩凯. 血清miR-103a,miR-30b,miR-29a 相对表达量对帕金森病的诊断效能[J]. 山东医药,2017,57(11):72-74.HAN Kai. Diagnostic efficacy of serum relativeexpression levels of miR-103a, miR-30b and miR-29afor Parkinson’s disease [J]. Shandong Medical, 2017,57 (11): 72-74.
[15] 许思, 王丽华, 王健健, 等. 神经系统疾病与循环microRNA 的研究进展[J]. 国际遗传学杂志, 2016,39(3):169-175.XU Si, WANG Lihua, WANG Jianjian, et al. Progressin studying on the relationship between nervous systemdiseases and circulating microRNA [J]. InternationalJournal of Genetics, 2016, 39 (3): 169-175.
[16] 张强, 王明洪, 甘敏, 等. 首发精神分裂症患者血清微小RNA-181c 水平与认知功能相关性分析[J].临床军医杂志, 2019, 47(9):965-966, 969.ZHANG Qiang, WANG Minghong, GAN Min, et al.Analysis on correlation between serum microRNA-181c level and cognitive function in patients with firstepisodeschizophrenia [J]. Clinical Journal of MedicalOfficers, 2019, 47 (9): 965-966, 969.
[17] 李泓江,孙兆良,杨西涛.microRNA 在中枢神经系统神经再生中作用[J]. 中国临床神经外科杂志,2016,21(10):646-648.LI Hongjiang, SUN Zhaoliang, YANG Xitao.The role of microRNA in central nervous systemnerve regeneration [J]. Chinese Journal of ClinicalNeurosurgery, 2016, 21 (10): 646-648.
[18] 王敏,聂思佩,朱玲玲,等. miR-206 调节的血清IGF-1 水平与2 型糖尿病伴发帕金森病的相关性研究 [J]. 药物评价研究, 2017, 40 (12): 1735-1740.WANG Min, NIE Sipei, ZHU Lingling, et al.Correlation study between serum IGF-1 levels regulatedby miR-206 and diabetes mellitus accompanied withParkinson’s disease [J]. Drug Evaluation Research,2017, 40 (12): 1735-1740.
[19] 王征,李艳芳.microRNA-146a 在2 型糖尿病周围神经病变患者血清中的表达及其临床意义[J]. 中国慢性病预防与控制,2019,27(1):28-31.WANG Zheng, LI Yanfang. Expression levels andclinical significance of serum microRNA-146a inpatients with type 2 diabetes mellitus plus diabeticperipheral neumpathy [J]. Chinese Journal ofPrevention and Control of Chronic Diseases, 2019,27(1): 28-31.
[20] 徐瑞, 刘贤, 牛梦月, 等.MiR-133b 对MPP+ 诱导的帕金森病多巴胺能神经元模型中酪氨酸羟化酶表达的影响[J]. 中国临床神经科学,2016,24(2):133-138.XU Rui, LIU Xian, NIU Mengyue, et al. Effect ofmiR-133b on expression of tyrosine hydroxylase in ratdopaminergic neuron primary culture injured by MPP+[J]. Chinese Journal of Clinical Neurosciences, 2016,24 (2): 133-138.
相似文献/References:
[1]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood
and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪a,张宝华b.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
WU Qia,ZHANG Bao-huab.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A
Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(05):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]李泽东,詹 贞,刘 忆,等.帕金森病患者血清鳞状细胞癌抗原(SCC-Ag)表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 / j.issn.1671-7414.2019.06.017]
LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(05):70.[doi:10.3969 / j.issn.1671-7414.2019.06.017]
[4]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(05):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[5]闫 欣,商素亮,李 娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(05):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[6]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(05):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[7]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4,MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(05):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[8]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(05):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[9]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(05):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]